Furthermore, recent findings indicate the particular importance of IFI16-STING in HER2+ breast cancer: IFI16-dependent STING activation is mechanistically important in anti-HER2 responses, and the epigenetic suppression of IFI16 is linked to resistance against anti-HER2 antibodies [243]. Here, IFI16 is linked to breast carcinoma.